Skip to main content
Premium Trial:

Request an Annual Quote

KineMed, Pfizer Renew Metabolic Disease Research Collaboration

Premium

NEW YORK (GenomeWeb News) – KineMed this week announced the renewal of its non-exclusive research collaboration with Pfizer into metabolic disease, and type 2 diabetes in particular.

The collaboration was originally established in 2013 and calls for KineMed to use its dynamic proteomics technology platform to map the impact of potential drug candidates.

KineMed's technology uses wide-scale isotopic labeling and mass spectrometry to track protein activity kinetics, which can elucidate biological pathways and disease processes.

This marks the second renewal of the two firms' collaboration, following an initial renewal announced in March.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.